Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2 alpha as molecular triggers?

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Nogueira, I (Author) Other; Dias, F (Author) Other; Morais, M (Author) Other; Teixeira, AL (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Future Oncology

Vol. 15

Pages: 2361-2370

ISSN: 1479-6694

Publisher: Future Medicine Ltd.

Indexing

ISI Web of Knowledge - 10 Citations

Scopus - 10 Citations

Other information

Authenticus ID: P-00Q-XKK

DOI: 10.2217/fon-2019-0067

Abstract (EN): Aim: The majority of clear cell renal cell carcinoma patients develop resistance to mTOR inhibitors. Materials & methods: As an in vitro model four cell lines were used: HKC-8, 786- O, RCC-FG-2 and an everolimus-resistant cell line (786-OR) established during this study. The quantification of miRNA-101 and HIF-2 alpha mRNA levels was assessed by real-time PCR. Results: We observed a significant decrease of miRNA-101 intracellular levels in 786-OR. However, this miRNA presented higher extracellular levels. Additionally, we found a significant increase of HIF-2 alpha in 786-OR. Conclusion: The circulating levels of miRNA-101 may be a potential biomarker of anti-mTOR therapy response and resistance prediction. Moreover, the resistance to mTOR inhibitors seems to be related with the overexpression of HIF-2 alpha.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10